Showing 2171-2180 of 2657 results for "".
- Eye PCR to Present Poster Presentations on Fixoflex, a New Intraocular Ophthalmic Implant Designed to Hold an IOL Inside Capsular Baghttps://modernod.com/news/eye-pcr-to-present-poster-presentations-on-fixoflex-a-new-intraocular-ophthalmic-implant-designed-to-hold-an-iol-inside-capsular-bag/2481087/At the ESCRS meeting in Milan, Italy, Eye PCR will provide Poster Presentations on Fixoflex, a new intraocular ophthalmic implant designed to hold an IOL minimizing any decentration and tilt inside of the eye’s natural capsular bag. According to Amsterdam-based Eye PCR,
- Rayner to Announce Launch of RayPRO+ Digital Health Platform at the ESCRShttps://modernod.com/news/rayner-to-announce-launch-of-raypro-digital-health-platform-at-the-escrs/2481082/Rayner announced the global launch of RayPRO+ at the upcoming ESCRS 2022 congress in Milan. RayPRO is Rayner’s proprietary mobile app and web-based digital platform that proactively collects a blend of patient reported outcomes (PROs) over 3 years. RayPRO+ has the added ability to
- Himalayan Cataract Project Appoints Katherine G. Overbey as CEOhttps://modernod.com/news/himalayan-cataract-project-appoints-katherine-g-overbey-as-ceo/2481070/The Himalayan Cataract Project (HCP) has named Katherine G. Overbey (K-T) its new Chief Executive Officer, effective as of October 4, 2022. As HCP enters its 28th year, HCP’s Board of Directors anticipates that Ms. Overbey will guide the organization in its mission to c
- iOR Partners Appoints Health Care Industry Veteran James R. Williams as New President and CEOhttps://modernod.com/news/ior-partners-welcomes-health-care-industry-veteran-as-new-president-and-ceo/2481068/iOR Partners announced that James R. Williams has been appointed to serve as the company’s new President and CEO. Mr. Williams joined iOR as Chief Operating Officer (COO) earlier this year and served on the iOR Board of Directors for 2 years. Mr. Williams brings over 30
- TearLab Announces Corporate Name Change to Trukera Medical; Targets Corneal Healthhttps://modernod.com/news/tearlab-announces-corporate-name-change-to-trukera-medical-targets-corneal-health/2481067/TearLab announced that it will be expanding its position in corneal health under the new name Trukera Medical. The rebranding reflects the company’s vision and future growth strategy targeting a broader set of unmet needs across corneal health. “We continue to rema
- SamaCare’s Prior Authorization Management Platform Available on the ModMed EMRhttps://modernod.com/news/samacares-prior-authorization-management-platform-available-on-the-modmed-emr/2481065/Retina and multi-specialty ophthalmology practices will now be able to synchronize data and share documents between the ModMed all-in-one ophthalmology solution and SamaCare’s prior authorization management platform, according to a SamaCare news release. The interface su
- Iveric Bio Announces Positive Topline Data from Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-positive-topline-data-from-zimura-gather2-phase-3-clinical-trial-in-geographic-atrophy/2481062/Iveric bio announced positive topline results from GATHER2, the company’s second phase 3 clinical trial of Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA). GATHER2 met its prespecified primary endpoint of mean r
- iTrack Canaloplasty to be Featured at the 2022 ESCRS Annual Meetinghttps://modernod.com/news/itrack-canaloplasty-to-be-featured-at-the-2022-escrs-annual-meeting/2481051/Nova Eye Medical announced that the company’s proprietary canaloplasty technology platform (iTrack™ and iTrack™ Advance) will be featured during the official scientific program of the European Society of Cataract and Refractive Surgeons (ESCRS) 40th Congress on Septemb
- Alcon to Acquire Aerie Pharmaceuticalshttps://modernod.com/news/alcon-to-acquire-aerie-pharmaceuticals/2481041/In another move to bolster its glaucoma portolio and expand its pharmaceutical offerings, Alcon announced it is acquiring Aerie Pharmaceuticals for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s lastest closing price. The transaction was a
- Study: Bioengineered Cornea Can Restore Sight to the Blind and Visually Impairedhttps://modernod.com/news/study-bioengineered-cornea-can-restore-sight-to-the-blind-and-visually-impaired/2481039/Researchers and entrepreneurs have developed an implant made of collagen protein from pig’s skin, which resembles the human cornea. In a pilot study, the implant restored vision to 20 people with diseased corneas, most of whom were blind prior to receiving the implant, according to Link&oum